title: Nrf2/ARE-mediated antioxidant actions of pro-electrophilic drugs.
abstract: Living cells maintain a balance between oxidation and reduction, and perturbations of this redox balance are thought to contribute to various diseases. Recent attempts to regulate redox state have focused on electrophiles (EPs), which activate potent cellular defense systems against oxidative stress. One example of this approach is exemplified by carnosic acid (CA) and carnosol (CS), compounds that are found in the herb rosemary (Rosmarinus officinalis). Importantly, CA and CS themselves are not electrophilic, but in response to oxidation, become electrophilic, and then activate the Keap1/Nrf2/ARE (antioxidant-response element) transcription pathway to synthesize endogenous antioxidant "phase 2" enzymes. As a result of our efforts to develop these compounds as therapeutics for brain health, we have formulated two innovative criteria for drug development: the first concept is the use of pro-electrophilic drugs (PEDs) that are innocuous in and of themselves; and the second concept involves the use of compounds that are pathologically activated therapeutics (PATs);i.e., these small molecules are chemically converted to their active form by the very oxidative stress that they are designed to then combat. The chemical basis for PED and PAT drugs is embodied in the ortho- and para-hydroquinone electrophilic cores of the molecules, which are oxidized by the Cu(2+)/Cu(+) cycling system (or potentially by other transition metals). Importantly, this cycling pathway is under stringent regulation by the cell redox state. We propose that redox-dependent quinone formation is the predominant mechanism for formation of PED and PAT drugs from their precursor compounds. In fact, redox-dependent generation of the active form of drug from the "pro-form" distinguishes this therapeutic approach from traditional EPs such as curcumin, and results in a decrease in clinical side effects at therapeutic concentrations, e.g., lack of reaction with other thiols such as glutathione (GSH), which can result in lowering GSH and inducing oxidative stress in normal cells. We consider this pro-drug quality of PED/PAT compoundsto be a key factor for generating drugs to be used to combat neurodegenerative diseases that will be clinically tolerated. Given the contribution of oxidative stress to the pathology of multiple neurodegenerative diseases, the Keap1/Nrf2/ARE pathway represents a promising drug target for these PED/PAT agents.
authors.affiliation: Del E. Webb Center for Neuroscience, Aging, and Stem Cell Research, Sanford-Burnham Medical Research Institute, 10901 North Torrey Pines Road, La Jolla, CA, USA; Department of Welfare Engineering, Faculty of Engineering, Iwate University, Morioka, Iwate 020-8551, Japan. Electronic address: tsatoh@sanfordburnham.org.
authors.forename: Takumi
authors.initials: T
authors.lastname: Satoh
authors.affiliation: Del E. Webb Center for Neuroscience, Aging, and Stem Cell Research, Sanford-Burnham Medical Research Institute, 10901 North Torrey Pines Road, La Jolla, CA, USA.
authors.forename: Scott R
authors.initials: SR
authors.lastname: McKercher
authors.affiliation: Del E. Webb Center for Neuroscience, Aging, and Stem Cell Research, Sanford-Burnham Medical Research Institute, 10901 North Torrey Pines Road, La Jolla, CA, USA. Electronic address: slipton@sanfordburnham.org.
authors.forename: Stuart A
authors.initials: SA
authors.lastname: Lipton
mesh_terms: D000818:Animals; D061745:Antioxidant Response Elements / Q000502:physiology*; D000975:Antioxidants / Q000737:chemistry* / Q000494:pharmacology*; D015195:Drug Design; D006801:Humans; D006873:Hydroquinones / Q000737:chemistry / Q000494:pharmacology; D051267:NF-E2-Related Factor 2 / Q000378:metabolism*; D018384:Oxidative Stress / Q000187:drug effects; D011355:Prodrugs / Q000737:chemistry / Q000494:pharmacology
chemical_list: D000975:Antioxidants; D006873:Hydroquinones; D051267:NF-E2-Related Factor 2; C495635:NFE2L2 protein, human; D011355:Prodrugs
keywords: ABCC; ARE; ATP-binding cassette, subfamily C; Antioxidant-response element; CA; CS; Carnosol; DA; DMF; DOX; Dimethyl fumarate (also known as BG-12); Dopamine; Doxorubicin (also known as adriamycin); EP; Electrophile; Electrophilic counterattack; GCLC; GCLM; GSH; GST; Glutamyl cysteine ligase catalytic subunit; Glutamyl cysteine ligase modifier subunit; Glutathione; Glutathione-S-transferase; H(2)O(2); HO-1; HSE; HSF-1; HSP; Heat-shock factor-1; Heat-shock protein; Hemeoxygenase-1; Hydrogen peroxide; Keap1; Kelch-like ECH-associated protein 1; MS; Multiplesclerosis; NADPH quinone oxidoreductase 1; NEPP; NGF; NQO1; Na(+)-independent cystine-glutamate exchanger; Nerve growth factor; Neurite outgrowth-promoting prostaglandin; Nrf2; Nuclear factor (erythroid-derived 2)-like 2; PAT; PD; PED; Parkinson's disease; Pathologically activated therapeutic; Pro-electrophilic drug; RNS; ROS; Reactive nitrogen species; Reactive oxygen species; STR; Strongylophorin; TBHQ; Tert-butylhydroquinone; carnosic acid; heat-responsive element; xCT
references.citation: Planta Med. 2006 Aug;72(10):881-7
references.pmid: 16858665
references.citation: Chem Res Toxicol. 2012 Sep 17;25(9):1893-901
references.pmid: 22894569
references.citation: J Pharm Sci. 2011 Aug;100(8):3139-3145
references.pmid: 21360710
references.citation: J Neurochem. 2011 Nov;119(3):569-78
references.pmid: 21883218
references.citation: J Pharmacol Exp Ther. 2012 Jul;342(1):169-76
references.pmid: 22511203
references.citation: Invest Ophthalmol Vis Sci. 2006 Jul;47(7):3164-77
references.pmid: 16799064
references.citation: Pharm Res. 2011 Nov;28(11):2680-94
references.pmid: 21818712
references.citation: J Neurosci Res. 2007 Feb 15;85(3):497-503
references.pmid: 17171703
references.citation: Chem Res Toxicol. 2005 Dec;18(12):1917-26
references.pmid: 16359182
references.citation: Biochem Pharmacol. 2008 Jul 1;76(1):91-7
references.pmid: 18508031
references.citation: Mediators Inflamm. 2012;2012:781375
references.pmid: 22577255
references.citation: Invest Ophthalmol Vis Sci. 1999 Aug;40(9):1927-35
references.pmid: 10440245
references.citation: Xenobiotica. 1992 Feb;22(2):257-68
references.pmid: 1378672
references.citation: Cell J. 2011 Spring;13(1):39-44
references.pmid: 23671826
references.citation: Free Radic Biol Med. 2009 Feb 15;46(4):492-501
references.pmid: 19071211
references.citation: Mol Cell Biol. 2004 Dec;24(24):10941-53
references.pmid: 15572695
references.citation: Sci Signal. 2009 Sep 29;2(90):re7
references.pmid: 19797270
references.citation: J Neurosci Res. 1999 Nov 1;58(3):436-41
references.pmid: 10518117
references.citation: Biochem Biophys Res Commun. 2009 May 8;382(3):549-54
references.pmid: 19289108
references.citation: Biochem Biophys Res Commun. 2005 Jan 14;326(2):371-7
references.pmid: 15582588
references.citation: J Gastroenterol. 2012 Jul;47(7):805-13
references.pmid: 22350699
references.citation: Neurochem Int. 2010 Nov;57(4):460-7
references.pmid: 20096739
references.citation: Biofactors. 2000;12(1-4):5-11
references.pmid: 11216505
references.citation: J Neurochem. 2000 Sep;75(3):1092-102
references.pmid: 10936191
references.citation: J Neurochem. 2007 Apr;101(1):109-19
references.pmid: 17394461
references.citation: J Biol Chem. 2004 Mar 5;279(10):8919-29
references.pmid: 14688281
references.citation: Arch Dermatol Res. 2013 Jul;305(5):447-51
references.pmid: 23525570
references.citation: J Biochem. 2010 Jan;147(1):73-81
references.pmid: 19762340
references.citation: J Bioenerg Biomembr. 2009 Dec;41(6):469-72
references.pmid: 19967436
references.citation: Neurosci Lett. 2008 Apr 4;434(3):260-5
references.pmid: 18329808
references.citation: Neurochem Int. 2011 Feb;58(3):248-60
references.pmid: 21130821
references.citation: Curr Treat Options Neurol. 2011 Dec;13(6):544-59
references.pmid: 21837392
references.citation: Acta Pharmacol Sin. 2010 Dec;31(12):1523-31
references.pmid: 21127495
references.citation: Neurosci Lett. 2000 Jul 14;288(2):163-6
references.pmid: 10876086
references.citation: Nature. 2010 Nov 11;468(7321):232-43
references.pmid: 21068832
references.citation: Eur J Neurosci. 2003 Jun;17(11):2249-55
references.pmid: 12814358
references.citation: Neurosci Lett. 2007 May 11;418(1):102-5
references.pmid: 17400379
references.citation: Planta Med. 2010 May;76(7):683-8
references.pmid: 19941258
references.citation: Hepatol Res. 2011 Jan;41(1):87-92
references.pmid: 21199201
references.citation: Biosci Biotechnol Biochem. 2012;76(1):115-9
references.pmid: 22232247
references.citation: Nature. 1993 Aug 12;364(6438):626-32
references.pmid: 8394509
references.citation: Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4796-803
references.pmid: 16303981
references.citation: Curr Top Med Chem. 2001 Dec;1(6):497-506
references.pmid: 11895126
references.citation: Free Radic Biol Med. 2004 May 15;36(10):1208-13
references.pmid: 15110385
references.citation: Free Radic Biol Med. 2011 Mar 1;50(5):567-75
references.pmid: 21163346
references.citation: Antioxid Redox Signal. 2010 Dec 1;13(11):1713-48
references.pmid: 20446772
references.citation: Toxicol Appl Pharmacol. 2010 May 15;245(1):21-35
references.pmid: 20116392
references.citation: J Neurochem. 2008 Feb;104(4):1116-31
references.pmid: 17995931
references.citation: J Nutr. 2011 Dec;141(12):2119-25
references.pmid: 22031657
references.citation: J Invest Dermatol. 2007 Apr;127(4):835-45
references.pmid: 17235328
references.citation: Biochem Biophys Res Commun. 2012 Feb 3;418(1):22-6
references.pmid: 22214931
references.citation: PLoS One. 2011 Jan 31;6(1):e16172
references.pmid: 21297955
references.citation: Genes Cells. 2011 Feb;16(2):123-40
references.pmid: 21251164
references.citation: J Neuropathol Exp Neurol. 2013 Jan;72(1):18-28
references.pmid: 23242280
references.citation: Prog Neurobiol. 2012 Jan;96(1):87-95
references.pmid: 22138392
references.citation: Drugs. 2013 May;73(7):625-50
references.pmid: 23609782
references.citation: Nat Rev Drug Discov. 2008 Dec;7(12):1013-30
references.pmid: 19043451
references.citation: Chem Biol. 2010 Jan 29;17(1):75-85
references.pmid: 20142043
references.citation: Trends Neurosci. 2007 Jan;30(1):37-45
references.pmid: 17137643
references.citation: Neuroreport. 2008 Aug 27;19(13):1301-4
references.pmid: 18695511
references.citation: J Biol Chem. 2003 Apr 4;278(14):12029-38
references.pmid: 12556532
references.citation: Int J Cell Biol. 2012;2012:463756
references.pmid: 22956959
references.citation: Biochem Biophys Res Commun. 2011 Nov 11;415(1):6-10
references.pmid: 21982768
references.citation: Neurosci Lett. 2004 Nov 16;371(1):1-5
references.pmid: 15500956
references.citation: Chem Biol Interact. 2011 Jun 30;192(1-2):101-6
references.pmid: 20846517
references.citation: Cancer Lett. 2006 Jun 8;237(1):130-6
references.pmid: 16019137
references.citation: Nat Rev Neurosci. 2007 Oct;8(10):803-8
references.pmid: 17882256
references.citation: J Diet Suppl. 2010 Dec;7(4):351-413
references.pmid: 22432564
references.citation: Biol Pharm Bull. 2003 Nov;26(11):1620-2
references.pmid: 14600414
references.citation: J Neurochem. 2001 Apr;77(1):50-62
references.pmid: 11279261
references.citation: J Neurochem. 2009 Jul;110(2):469-85
references.pmid: 19457088
references.citation: Int Dent J. 2011 Dec;61(6):287-96
references.pmid: 22117784
references.citation: J Pharmacol Exp Ther. 2012 Apr;341(1):274-84
references.pmid: 22267202
references.citation: Antioxid Redox Signal. 2011 Apr 15;14(8):1421-4
references.pmid: 20977364
references.citation: Exp Eye Res. 2008 Feb;86(2):366-74
references.pmid: 18160067
references.citation: Am J Clin Nutr. 1996 May;63(5):797S-811S
references.pmid: 8615367
references.citation: J Ethnopharmacol. 2010 Sep 15;131(2):451-8
references.pmid: 20633629
references.citation: Chem Biol. 2011 Nov 23;18(11):1355-61
references.pmid: 22118669
references.citation: Biochem Biophys Res Commun. 2009 Feb 6;379(2):537-41
references.pmid: 19118528
references.citation: J Biochem. 2011 Nov;150(5):473-5
references.pmid: 21908547
references.citation: Food Chem Toxicol. 2011 Dec;49(12):3090-7
references.pmid: 21930180
references.citation: Molecules. 2010 Nov 03;15(11):7792-814
references.pmid: 21060289
references.citation: Mol Interv. 2010 Feb;10(1):39-50
references.pmid: 20124562
references.citation: Pharmacol Rev. 2012 Oct;64(4):972-1003
references.pmid: 22966038
references.citation: Genes Dev. 2008 Jun 1;22(11):1427-38
references.pmid: 18519635
references.citation: J Neurochem. 1998 Jul;71(1):69-77
references.pmid: 9648852
references.citation: Biol Chem. 2003 Apr;384(4):505-16
references.pmid: 12751781
references.citation: Biochem Biophys Res Commun. 2012 Jan 6;417(1):294-8
references.pmid: 22155240
references.citation: Biochem Mol Biol Int. 1993 Apr;29(5):807-20
references.pmid: 8508133
references.citation: Invest Ophthalmol Vis Sci. 2012 Nov 27;53(12):7847-54
references.pmid: 23081978
references.citation: J Neurosci. 2004 Feb 4;24(5):1101-12
references.pmid: 14762128
references.citation: Curr Opin Chem Biol. 2011 Feb;15(1):162-73
references.pmid: 21195017
references.citation: Neuropharmacology. 1994 Nov;33(11):1229-33
references.pmid: 7870283
references.citation: J Biochem. 2011 Aug;150(2):209-17
references.pmid: 21596795
references.citation: Trends Biochem Sci. 2005 Aug;30(8):453-61
references.pmid: 15996871
references.citation: Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):768-73
references.pmid: 16407140
references.citation: Ageing Res Rev. 2008 Jan;7(1):1-7
references.pmid: 18162444
references.citation: Antioxid Redox Signal. 2010 Dec 1;13(11):1763-811
references.pmid: 20446769
references.citation: Chem Res Toxicol. 2008 Apr;21(4):805-12
references.pmid: 18361512
references.citation: J Neurochem. 2008 Nov;107(3):690-700
references.pmid: 18702664
references.citation: Recent Pat CNS Drug Discov. 2012 Dec;7(3):218-29
references.pmid: 22742419
references.citation: Neurochem Res. 2009 Apr;34(4):698-706
references.pmid: 18770028
references.citation: Curr Drug Targets CNS Neurol Disord. 2005 Jun;4(3):267-81
references.pmid: 15975029
references.citation: Nat Rev Drug Discov. 2006 Feb;5(2):160-70
references.pmid: 16424917